Some innovative drugs (antibody drug conjugates, CDK4/6 inhibitors, PARP inhibitors, selective estrogen degraders, and immune checkpoint inhibitors) have allowed for considerable improvements in outcomes for patients with breast cancer of all subtypes. The gene discussed is CDK4; the disease is breast carcinoma.